Get the Stockscreener App
8.13
4.24%
-0.36
After Hours:
8.12
-0.01
-0.12%
Eupraxia Pharmaceuticals Inc stock is traded at $8.13, with a volume of 82,055.
It is down -4.24% in the last 24 hours and down -0.85% over the past month.
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs.
See More
Previous Close:
$8.49
Open:
$8.37
24h Volume:
82,055
Relative Volume:
0.52
Market Cap:
$411.77M
Revenue:
-
Net Income/Loss:
$-29.42M
P/E Ratio:
-9.3588
EPS:
-0.8687
Net Cash Flow:
$-25.01M
1W Performance:
-3.90%
1M Performance:
-0.85%
6M Performance:
+51.30%
1Y Performance:
+155.66%
1-Day Range:
$8.02
$8.37
1-Week Range:
$8.02
$8.78
52-Week Range:
$2.6801
$9.32
Eupraxia Pharmaceuticals Inc Stock (EPRX) Company Profile
Name
Eupraxia Pharmaceuticals Inc
Sector
Industry
Phone
-
Address
-
Compare EPRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EPRX
Eupraxia Pharmaceuticals Inc
|
8.13 | 430.00M | 0 | -29.42M | -25.01M | -0.8687 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Eupraxia Pharmaceuticals Inc Stock (EPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-24-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-26-25 | Initiated | H.C. Wainwright | Buy |
| Jun-16-25 | Initiated | Canaccord Genuity | Speculative Buy |
| Feb-21-25 | Initiated | Craig Hallum | Buy |
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
Eupraxia Pharmaceuticals Inc Stock (EPRX) Latest News
(EPRX.WT.A) Equity Trading Insights - Stock Traders Daily
Rate Hike: What are Eupraxia Pharmaceuticals Incs recent SEC filings showingWeekly Profit Report & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
(EPRX) Stock Trading Blueprint (EPRX:CA) - Stock Traders Daily
Can Eupraxia Pharmaceuticals Inc. stock deliver sustainable ROEQuarterly Trade Report & Daily Profit Focused Stock Screening - mfd.ru
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Given Average Rating of "Buy" by Brokerages - MarketBeat
(EPRX.WT.A) Strategic Investment Guide - Stock Traders Daily
Risk Off: Is Eupraxia Pharmaceuticals Inc affected by consumer sentimentWeekly Earnings Recap & Safe Entry Momentum Stock Tips - baoquankhu1.vn
Valuation Update: Can Eupraxia Pharmaceuticals Inc beat the S P 500July 2025 Reactions & Community Consensus Trade Signals - baoquankhu1.vn
Is HBOS plc Preferred Security forming a double bottomWeekly Earnings Recap & Real-Time Price Movement Reports - baoquankhu1.vn
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Price Down 3.8%What's Next? - MarketBeat
(EPRX.WT.A) Advanced Trading Insights - Stock Traders Daily
Eupraxia Pharmaceuticals (TSX:EPRX) Trades With S&P/TSX Index - Kalkine Media
Here's Why We're Not At All Concerned With Eupraxia Pharmaceuticals' (TSE:EPRX) Cash Burn Situation - Yahoo Finance
(EPRX) Optimized Trading Opportunities (EPRX:CA) - Stock Traders Daily
(EPRX.WT.A) Trading Strategy and Analysis - Stock Traders Daily
(EPRX) Market Performance Analysis (EPRX:CA) - Stock Traders Daily
Fed Watch: Will Eupraxia Pharmaceuticals Inc stock hit new highs in YEAR - baoquankhu1.vn
(EPRX.WT.A) Investment Analysis (EPRX.WT.A:CA) - Stock Traders Daily
(EPRX) Technical Data (EPRX:CA) - Stock Traders Daily
Osteoarthritis Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Merck, Peptinov, LG Chem, Akan Bioscience, BioTissue,Inc., Eupraxia Pharma - Barchart.com
Osteoarthritis Pipeline 2025: MOA And ROA Insights, Clinical Trials Status, And Key Companies Involved By Delveinsight Merck, Peptinov, LG Chem, Akan Bioscience, Biotissue,Inc., Eupraxia Pharma - Menafn.com
Momentum Shift: Does Ainos Inc have strong fundamentalsPortfolio Value Report & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
(EPRX.WT.A) Technical Data (EPRX.WT.A:CA) - Stock Traders Daily
Gains Report: Will APWS stock hit new highs in YEARQuarterly Trade Report & Community Verified Watchlist Alerts - baoquankhu1.vn
Shorts Report: Will Eupraxia Pharmaceuticals Inc stock hit new highs in YEARTrade Signal Summary & Verified Trade Idea Suggestions - baoquankhu1.vn
Eupraxia Pharmaceuticals (OTCMKTS:EPRXF) Trading Down 0.1% – Time to Sell? - Defense World
Market Overview: What is Eupraxia Pharmaceuticals Incs valuation compared to sectorMarket Activity Report & Community Verified Watchlist Alerts - baoquankhu1.vn
(EPRX) Daily Stock Insights (EPRX:CA) - Stock Traders Daily
(EPRX.WT.A) Dynamic Trading Report - Stock Traders Daily
Risk Report: Whats the beta of Eupraxia Pharmaceuticals Inc stock2025 Macro Impact & AI Powered Market Entry Strategies - baoquankhu1.vn
Targets Report: Is PNFP a top pick in the sectorJuly 2025 Trade Ideas & Capital Efficiency Focused Strategies - baoquankhu1.vn
(EPRX) Strategic Market Analysis (EPRX:CA) - Stock Traders Daily
Aug Retail: What are Eupraxia Pharmaceuticals Incs recent SEC filings showingWeekly Trade Report & Real-Time Volume Trigger Notifications - baoquankhu1.vn
Aug Catalysts: Will Eupraxia Pharmaceuticals Inc benefit from rising consumer demand2025 Market Overview & Smart Swing Trading Alerts - baoquankhu1.vn
(EPRX) Trading Advice (EPRX:CA) - Stock Traders Daily
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Price Target Raised to $19.00 at Cantor Fitzgerald - Defense World
Cantor Fitzgerald Raises Eupraxia Pharmaceuticals (NASDAQ:EPRX) Price Target to $19.00 - MarketBeat
Cantor Fitzgerald raises Eupraxia Pharmaceuticals stock price target to $19 By Investing.com - Investing.com UK
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Receives Average Rating of "Buy" from Analysts - MarketBeat
Eupraxia Pharmaceuticals (TSX:EPRX) Price Target Increased by 21.11% to 14.96 - Nasdaq
Short Interest in Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Grows By 138.8% - MarketBeat
Eupraxia Pharmaceuticals (EPRX) Price Target Increased by 21.61% to 10.82 - Nasdaq
(EPRX.WT.A) Investment Performance Report - Stock Traders Daily
Trend Report: What is Eupraxia Pharmaceuticals Incs valuation compared to sectorMarket Trend Review & Free Accurate Trade Setup Notifications - baoquankhu1.vn
Trading Action: Will Eupraxia Pharmaceuticals Inc benefit from rising consumer demandMarket Trend Summary & High Conviction Buy Zone Picks - baoquankhu1.vn
Macro Review: Can Eupraxia Pharmaceuticals Inc grow without dilution2025 Institutional Moves & Safe Entry Momentum Stock Tips - baoquankhu1.vn
Trend Tracker for (EPRX) (EPRX:CA) - Stock Traders Daily
(EPRX) Trading Strategy and Analysis (EPRX:CA) - Stock Traders Daily
Can Eupraxia Pharmaceuticals Inc. stock sustain institutional interest2025 Key Highlights & Expert Verified Movement Alerts - Улправда
Eupraxia Pharmaceuticals’ (EPRX) Buy Rating Reaffirmed at HC Wainwright - Defense World
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Given Buy Rating at HC Wainwright - MarketBeat
Eupraxia Pharmaceuticals Inc Stock (EPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):